Informationen:
Fehler:
ID
31141
Beschreibung
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.; ODM derived from: https://clinicaltrials.gov/show/NCT00773383
Link
https://clinicaltrials.gov/show/NCT00773383
Stichworte
Versionen (1)
- 23.07.18 23.07.18 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
23. Juli 2018
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Non-Small Cell Lung Cancer NCT00773383
Eligibility Non-Small Cell Lung Cancer NCT00773383
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Non-Small Cell Lung Cancer NCT00773383
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Age | Non-Small Cell Lung Carcinoma Inoperable TNM clinical staging | Non-Small Cell Lung Carcinoma Advanced Locally TNM clinical staging | Non-small cell lung cancer metastatic TNM clinical staging
Item
male or female patients >=18 years with histologically documented inoperable, locally advanced or metastatic (stage iiib or iv) nsclc;
boolean
C0001779 (UMLS CUI [1])
C0007131 (UMLS CUI [2,1])
C0205187 (UMLS CUI [2,2])
C3258246 (UMLS CUI [2,3])
C0007131 (UMLS CUI [3,1])
C0205179 (UMLS CUI [3,2])
C1517927 (UMLS CUI [3,3])
C3258246 (UMLS CUI [3,4])
C0278987 (UMLS CUI [4,1])
C3258246 (UMLS CUI [4,2])
C0007131 (UMLS CUI [2,1])
C0205187 (UMLS CUI [2,2])
C3258246 (UMLS CUI [2,3])
C0007131 (UMLS CUI [3,1])
C0205179 (UMLS CUI [3,2])
C1517927 (UMLS CUI [3,3])
C3258246 (UMLS CUI [3,4])
C0278987 (UMLS CUI [4,1])
C3258246 (UMLS CUI [4,2])
Tarceva | Standard Chemotherapy Quantity failed
Item
currently receiving tarceva monotherapy and having failed at least one standard chemotherapy regimens;
boolean
C1135136 (UMLS CUI [1])
C1442989 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0231175 (UMLS CUI [2,4])
C1442989 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0231175 (UMLS CUI [2,4])
Tarceva | Response Previous | Stable Disease Previous
Item
prior response or stable disease 12 weeks from start of tarceva;
boolean
C1135136 (UMLS CUI [1])
C1704632 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C0677946 (UMLS CUI [3,1])
C0205156 (UMLS CUI [3,2])
C1704632 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C0677946 (UMLS CUI [3,1])
C0205156 (UMLS CUI [3,2])
Progressive Disease
Item
documented progressive disease at enrollment;
boolean
C1335499 (UMLS CUI [1])
Measurable Disease
Item
measurable disease according to the recist criteria;
boolean
C1513041 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status 0-2;
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life expectancy >12 weeks.
boolean
C0023671 (UMLS CUI [1])
Central nervous system lesion
Item
patients with active cns lesions;
boolean
C0742468 (UMLS CUI [1])
IGF-1R inhibitors | EGFR Targeted Therapy
Item
prior treatment with agents acting via igf-1r inhibition or egfr targeting;
boolean
C4044495 (UMLS CUI [1,1])
C0243077 (UMLS CUI [1,2])
C0034802 (UMLS CUI [2,1])
C2985566 (UMLS CUI [2,2])
C0243077 (UMLS CUI [1,2])
C0034802 (UMLS CUI [2,1])
C2985566 (UMLS CUI [2,2])
CORTICOSTEROIDS FOR SYSTEMIC USE High dose
Item
administration with high doses of systemic corticosteroids;
boolean
C3653708 (UMLS CUI [1,1])
C0444956 (UMLS CUI [1,2])
C0444956 (UMLS CUI [1,2])
Therapeutic radiology procedure
Item
radiotherapy in the 4 weeks prior to study start;
boolean
C1522449 (UMLS CUI [1])
Operative Surgical Procedures | Traumatic injury
Item
surgery or significant traumatic injury with in the last 2 weeks prior to study start.
boolean
C0543467 (UMLS CUI [1])
C3263723 (UMLS CUI [2])
C3263723 (UMLS CUI [2])